

Table SI. Cumulative incidence of cutaneous immune-related adverse events (n = 189)

Category (bold) or type of cirAE	n (%)
Inflammatory dermatoses	73 (38.6%)
Psoriasis	5 (2.6%)
Pruritus	35 (18.5%)
Eczema	20 (10.6%)
Seborrheic dermatitis	10 (5.3%)
Others types of eczema	12 (5.8%)
Maculopapular rash	8 (4.2%)
Lichenoid eruptions	5 (2.6%)
Rosacea	1 (0.5%)
Folliculitis	3 (1.6%)
Hidradenitis suppurativa	2 (1.1%)
Prurigo	1 (0.5%)
Urticarial reaction	4 (2.1%)
Fixed drug rash	1 (0.5%)
Mucositis	1 (0.5%)
Pseudolymphoma	1 (0.5%)
Genital lichen sclerosis	1 (0.5%)
Perioral dermatitis	1 (0.5%)
Sarcoidosis	1 (0.5%)
Sweet-like reaction	1 (0.5%)
Alteration of keratinocytes	12 (6.3%)
Actinic keratosis	1 (0.5%)
Basal-cell carcinoma	2 (1.1%)
Xerosis	8 (4.2%)
Hair disorders	2 (1.1%)
Grover disease	1 (0.5%)
Immunobullous eruptions	1 (0.5%)
Bullous pemphigoid	1 (0.5%)
Pigmentary changes	5 (2.6%)
Vitiligo	5 (2.6%)
Halo nevus	2 (1.1%)
NOS eruptions*	5 (2.6%)

*We were unable to visualize these rashes owing to acute presentation, trivialization by the oncologist or improvement before assessment; therefore, we could not specify type, category, grade or necessity of biopsy.

n: number of participants; cirAE: cutaneous immune-related adverse events; NOS: not otherwise specified.

Table SII. Mortality and progression rates.

Variable	Mortality per 100 patient-years (95 CI%)	Progression per 100 patient-years (95% CI)
Cancer type		
Melanoma	9.4 (3.9-22.6)	60.9 (33.7-109.9)
Kidney/urinary	15.8 (9.1-27.2)	123.6 (81.4-187.7)
NSCLC	37.4 (29.8-46.9)	130.9 (106.5-161.0)
Others	14.5 (9.0-23.4)	58.0 (37.4-89.9)
Melanoma		
No	26.2 (21.6-31.7)	109.1 (92.0-129.4)
Yes	9.4 (3.9-22.6)	60.9 (33.7-109.9)
cirAEs		
No	35.9 (28.8-44.8)	146.2 (118.8-179.9)
Yes	13.3 (9.3-18.9)	69.1 (52.9-90.2)

CI, confidence interval; cirAE, cutaneous immune-related adverse event; NSCLC, non-small-cell lung cancer.